Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

Skin cancer drug sonidegib approved in United States

The US Food and Drug Administration has approved sonidegib (Novartis’s Odomzo) as a treatment for patients with locally advanced basal cell carcinoma (micrograph pictured) that has recurred following surgery or radiation therapy

Source: Nephron / Wikimedia Commons

US patients with basal cell carcinoma have a new treatment option after the FDA approved sonidegib

The US Food and Drug Administration (FDA) has approved sonidegib (Novartis’s Odomzo) as a treatment for patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, as well as for patients who are not candidates for surgery or radiation therapy.

Sonidegib is taken once a day and works by inhibiting a molecular pathway known as the Hedgehog pathway, which is active in basal cell cancers. By suppressing the pathway, the drug may reduce the growth of cancerous lesions. It is the second drug that interferes with this pathway to be approved for basal cell carcinoma by the FDA in recent years; vismodegib (Erivedge) was approved in 2012.

In a clinical trial, the tumours of 58% of patients taking sonidegib 200mg daily shrank or disappeared, with the effects lasting from 1.9 months to 18.6 months.

Sonidegib will carry a warning that it may cause death or severe birth defects in a developing foetus when administered to a pregnant woman. The drug also has the potential to cause serious musculoskeletal-related side effects, including increased serum creatine kinase levels (with rare reports of rhabdomyolysis), muscle spasms and myalgia.

Common side effects with sonidegib include muscle spasms, alopecia, dysgeusia (distortion in the sense of taste), fatigue, nausea, musculoskeletal pain, diarrhoea, decreased weight, decreased appetite, myalgia, abdominal pain, headache, pain, vomiting and pruritus.

The European Medicines Agency issued a positive opinion on sonidegib on 25 June 2015. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069067

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The US Food and Drug Administration has approved sonidegib (Novartis’s Odomzo) as a treatment for patients with locally advanced basal cell carcinoma (micrograph pictured) that has recurred following surgery or radiation therapy

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.